Multiple sclerosis (MS) is a condition that disrupts the information pathways that connect your brain and your body. From time to time, the symptoms of MS can unexpectedly worsen. When symptoms ...

“Our data add and expand previous observations on silent progression in MS and are consistent with the view of the disease as a single continuum, in which RAW [relapse-associated worsening] and PIRA ...

The quest to understand and slow disease progression in multiple sclerosis (MS) continued in 2024, with research revealing possible new treatments and furthering knowledge about the disease course.

Briumvi is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.

(Barcelona, Spain, Wednesday, 24 September 2025) New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ...

Mavenclad (cladribine) is a medicine used to treat relapsing forms of multiple sclerosis (MS) including relapsing-remitting MS and active secondary progressive MS. Relapsing forms of MS have temporary ...

Over one-third of MS patients do not fully recover post-relapse, with severity as the strongest predictor of incomplete recovery. Relapse-associated worsening (RAW) is crucial in understanding ...

OTTAWA — The use of oral rather than intravenous (IV) steroids to respond to relapses in patients with relapsing-remitting multiple sclerosis (RRMS) is growing, a study suggested. The data, which were ...

Please provide your email address to receive an email when new articles are posted on . Chart review yielded 38 persons with MS and cancer treated with immune checkpoint inhibitors. Thirteen patients ...

Restricted coverage of medications for relapsing-remitting multiple sclerosis (MS) was associated with a higher risk for relapse, a new study showed. Patients with MS enrolled in Medicare Advantage ...

Relapsing-remitting multiple sclerosis (MS) is commonly treated with parenteral drugs that can lead to adverse events and poor adherence. Three phase 3 randomized trials evaluated the efficacy and ...

People with multiple sclerosis (MS) have an increased risk of severe coronavirus infection, but there has been concern regarding potential relapse after vaccination. A new study finds that people with ...